Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Plain-language summary
This Phase 1, Phase 2 trial is evaluating Linperlisib in combination with CHOP as a treatment for people newly diagnosed with T-cell lymphoma. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Linperlisib in combination with CHOP (DRUG): Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
- Drugs / treatments
- Linperlisib in combination with CHOP
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details